Evidence-Based Nursing for Fatigue and Quality of Life in Lung Cancer Chemotherapy

Inclusion Criteria: * Pathologically or radiologically confirmed lung cancer (World Health Organization \[WHO\] 2021 diagnostic criteria). * Scheduled to receive first-line chemotherapy (platinum-based regimen). * Karnofsky Performance Status (KPS) score ≥60. * Estimated survival time \>6 months (assessed by treating oncologist). * Normal mental and cognitive function (Mini-Mental State Examination \[MMSE\] score ≥24). * Voluntary participation and signed informed consent. Exclusion Criteria: * Concurrent severe organ dysfunction (Child-Pugh score ≥B for liver; estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m² for kidney). * Active neurological disorders (e.g., stroke, epilepsy) affecting symptom reporting. * Acute infectious diseases (e.g., tuberculosis with sputum positivity). * Known allergies to chemotherapy drugs (e.g., platinum agents). * Acute illnesses requiring hospitalization (e.g., pneumonia, myocardial infarction). * Secondary malignancies (pathologically confirmed). * Chemotherapy contraindications (e.g., uncontrolled heart failure). * Inability to communicate in the local language (assessed via nurse interview). * Concurrent radiotherapy or immunotherapy. * Participation in other interventional clinical trials within 3 months.